Advertisement
Northern Optotronics, Inc. joins the growing list of internationaldistributors for ActiPatch Therapy. BioElectronics has signed agreements inplace and shipping has commenced to Germany, Kuwait, Singapore, Malaysia,Turkey, Columbia, the United Kingdom, Italy, the Netherlands, Panama, andMexico. The Company expects to ship product to both Saudi Arabia and Korea bymonth's end.
Advertisement
"We are pleased to be working with Northern Optotronics to bring thehealing benefits of ActiPatch to Canadian medical market. We look forward toa long and mutually beneficial relationship", said Andrew Whelan ofBioElectronics.
"Northern Optotronics official product launch of ActiPatch began thisweek. We are extremely excited about the market potential for thisinnovative, drug-free therapy. We are planning an all out blitz to introduceActiPatch and we expect to have significant sales revenue from ActiPatchproducts," said Mr. Ross McDonald of Northern Optotronics Inc.
About Northern Optotronics:
Northern Optotronics was established in 1997 and employs 8 sales agentswith a total staff of 22. The Company distributes medical/aesthetic lasers andophthalmic products.
For more information visit http://www.noi.ca
About BioElectronics:
BioElectronics Corporation is the maker of ActiPatch(TM). ActiPatch is adrug-free anti-inflammatory patch with an embedded battery operated microchipthat delivers weeks of continuous pulsed therapy for less than a dollar a day.The unique ActiPatch delivery system, using patented technology, provides acost-effective, patient friendly method to reduce soft tissue pain andswelling.
For more information visit http://www.bioelectronicscorp.com
Safe Harbor Statement:
This news release contains forward-looking statements related to futuregrowth and earnings opportunities. Such statements are based upon certainassumptions and assessments made by management of both companies in light ofcurrent conditions, expected future developments and other factors it believesto be appropriate. Actual results may differ as a result of factors over whichthe companies have no control.
SOURCE BioElectronics Corporation
